Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 7/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7840132 | 0.84 | ESR1 (0.42) | BRD4CREBBP | |
| SCHEMBL13475983 | 0.74 | ACHE (0.40) | ACHEMAOBBRD4CREBBP | |
| SCHEMBL14449384 | 0.74 | ACHE (0.40) | ACHEMAOBBRD4CREBBP | |
| SCHEMBL7916564 | 0.73 | CREBBP (0.50) | ACHEMAOBBRD4CREBBP | |
| SCHEMBL21657656 | 0.73 | CREBBP (0.50) | ACHEMAOBBRD4CREBBP | |
| SCHEMBL27541843 | 0.70 | MAOB (0.39) | ACHEMAOBBRD4CREBBP | |
| SCHEMBL18469508 | 0.69 | HIF1A (0.44) | ACHEMAOB | |
| SCHEMBL12433393 | 0.67 | ALOX15B (0.43) | ACHEMAOB | |
| SCHEMBL13059463 | 0.65 | CA2 (0.40) | ACHEMAOB | |
| SCHEMBL10262750 | 0.64 | CREBBP (0.41) | ACHEMAOBBRD4CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785424-B2 | ngCycloartanone derivatives with anticancer activity | PIERRE FABRE MEDICAMENT (FR) | 2014-07-22 | — | — | US | disclosed |
| US-20120077777-A1 | NGCYCLOARTANONE DERIVATIVES WITH ANTICANCER ACTIVITY | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077777-A1 | NGCYCLOARTANONE DERIVATIVES WITH ANTICANCER ACTIVITY | PKD1, NME1, NGLY1 | ACHE 4807/4885MAOB 3420/4885BRD4 2199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.